Cited by 216Lung Cancer Treatments and MutationsCancer Genomics and DiagnosticsHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR

Watanabe, Masaru, Kawaguchi, Tomoya, Isa, Shun-ichi, Ando, Masahiko, Tamiya, Akihiro, Kubo, Akihito, Saka, Hideo, Takeo, Sadanori, Adachi, Hirofumi, Tagawa, Tsutomu, Kakegawa, Seiichi, Yamashita, Motohiro, Kataoka, Kazuhiko, Ichinose, Yukito, Takeuchi, Yukiyasu, Sakamoto, Kazuhiro, Matsumura, Akihide, Koh, Yasuhiro·2015·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-14-2151

Published version of a preprint

Open this paper in CoChat — free account

Abstract

PURPOSE: The resistance to the EGFR tyrosine kinase inhibitors (TKI) is a major concern in non-small cell lung cancer (NSCLC) treatment. T790M mutation in EGFR accounts for nearly 50% of the acquired resistance to EGFR-TKIs. Earlier studies suggested that T790M mutation was also detected in TKI-naïve NSCLCs in a small cohort. Here, we use an ultra-sensitive droplet digital PCR (ddPCR) technique to address the incidence and clinical significance of pretreatment T790M in a larger cohort. EXPERIMENTAL DESIGN: ddPCR was established as follows: wild-type or T790M mutation-containing DNA fragments were cloned into plasmids. Candidate threshold was identified using wild-type plasmid, normal human genomic DNA, and human A549 cell line DNA, which expresses wild type. Surgically resected tumor tissues from 373 NSCLC patients with EGFR-activating mutations were then examined for the presence of T790M using ddPCR. RESULTS: Our data revealed a linear performance for this ddPCR method (R(2) = 0.998) with an analytical sensitivity of approximately 0.001%. The overall incidence of the pretreatment T790M mutation was 79.9% (298/373), and the frequency ranged from 0.009% to 26.9%. The T790M mutation was detected more frequently in patients with a larger tumor size (P = 0.019) and those with common EGFR-activating mutations (P = 0.022), as compared with the others. CONCLUSIONS: The ultra-sensitive ddPCR assay revealed that pretreatment T790M was found in the majority of NSCLC patients with EGFR-activating mutations. ddPCR should be utilized for detailed assessment of the impact of the low frequency pretreatment T790M mutation on treatment with EGFR-TKIs.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-2151

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Self-citation
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
Digital PCR
Vogelstein, B., & Kinzler, K. W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9236 · Cited by 1,770
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8494 · Cited by 820
Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
Oxnard, G. R., Paweletz, C. P., Kuang, Y., Mach, S. L., O'Connell, A., Messineo, M. M., Luke, J. J., Butaney, M., Kirschmeier, P., Jackman, D. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2482 · Cited by 786
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O. H. Y., Eberg, M., Benayoun, S., Aprikian, A. G., Batist, G., Suissa, S., & Azoulay, L. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 661
Quantitative and sensitive detection of rare mutations using droplet-based microfluidics
Pekin, D., Skhiri, Y., Baret, J., Corre, D. L., Mažutis, L., Salem, C. B., Millot, F., Harrak, A. E., Hutchison, J. B., Larson, J. W., et al. (2011) · Lab on a Chip · doi:10.1039/c1lc20128j · Cited by 536
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
Chmielecki, J., Foo, J., Oxnard, G. R., Hutchinson, K. E., Ohashi, K., Somwar, R., Wang, L., Amato, K. R., Arcila, M. E., Sos, M. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002356 · Cited by 529
Digital PCR hits its stride
Baker, M. (2012) · Nature Methods · doi:10.1038/nmeth.2027 · Cited by 525
Multiplex Picodroplet Digital PCR to Detect KRAS Mutations in Circulating DNA from the Plasma of Colorectal Cancer Patients
Taly, V., Pekin, D., Benhaïm, L., Kotsopoulos, S. K., Corre, D. L., Li, X., Atochin, I., Link, D. R., Griffiths, A. D., Pallier, K., et al. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.206359 · Cited by 511
Pretreatment Epidermal Growth Factor Receptor ( EGFR ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
Su, K.-Y., Chen, H.-Y., Li, K.-C., Kuo, M.-L., Yang, J. C.-H., Chan, W.-K., Ho, B.-C., Chang, G.-C., Shih, J.-Y., Yu, S.-L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3224 · Cited by 499
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
Ohashi, K., Maruvka, Y. E., Michor, F., & Pao, W. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3912 · Cited by 467
Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer
Wu, J.-Y., Yu, C.-J., Chang, Y.-C., Yang, C.-H., Shih, J.-Y., & Yang, P.-C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3408 · Cited by 463
Presence ofEpidermal Growth Factor ReceptorGene T790M Mutation as a Minor Clone in Non–Small Cell Lung Cancer
Inukai, M., Toyooka, S., Ito, S., Asano, H., Ichihara, S., Soh, J., Suehisa, H., Ouchida, M., Aoe, K., Aoe, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1951 · Cited by 450
Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer
Beaver, J. A., Jelovac, D., Sasidharan, B., Cochran, R. L., Croessmann, S., Zabransky, D. J., Wong, H. Y., Toro, P. V., Cidado, J. R., Blair, B. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2933 · Cited by 404
New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer
Oxnard, G. R., Arcila, M. E., Chmielecki, J., Ladanyi, M., Miller, V. A., & Pao, W. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2571 · Cited by 359
Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations
Rosell, R., Molina, M. A., Costa, C., Simonetti, S., Gimenez-Capitan, A., Bertran-Alamillo, J., Mayo, C., Moran, T., Mendez, P., Cardenal, F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2158 · Cited by 304
The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial
Costa, C., Molina, M. A., Drozdowskyj, A., Giménez-Capitán, A., Bertran-Alamillo, J., Karachaliou, N., Gervais, R., Massuti, B., Wei, J., Moran, T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2233 · Cited by 229
Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing
Yu, H. A., Arcila, M. E., Hellmann, M. D., Kris, M. G., Ladanyi, M., & Riely, G. J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt573 · Cited by 206
A Rapid, Sensitive Assay to Detect EGFR Mutation in Small Biopsy Specimens from Lung Cancer
Yatabe, Y., Hida, T., Horio, Y., Kosaka, T., Takahashi, T., & Mitsudomi, T. (2006) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2006.050104 · Cited by 186
First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M).
Sequist, L. V. D., Soria, J., Gadgeel, S. M., Wakelee, H. A., Camidge, D. R., Varga, A., Solomon, B., Papadimitrakopoulou, V. A., Jaw‐Tsai, S., Caunt, L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8010 · Cited by 143
Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC).
Janne, P. A., Ramalingam, S. S., Yang, J. C., Ahn, M., Kim, D., Kim, S., Planchard, D., Ohe, Y., Felip, E., Watkins, C. L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8009 · Cited by 140
Multiplex Picoliter-Droplet Digital PCR for Quantitative Assessment of DNA Integrity in Clinical Samples
Didelot, A., Kotsopoulos, S. K., Mansuet‐Lupo, A., Pekin, D., Li, X., Atochin, I., Srinivasan, P., Zhong, Q., Olson, J., Link, D. R., et al. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.193409 · Cited by 122
Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation
Fujita, Y., Suda, K., Kimura, H., Matsumoto, K., Arao, T., Nagai, T., Saijo, N., Yatabe, Y., Mitsudomi, T., & Nishio, K. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182653d7f · Cited by 119
Detecting biomarkers with microdroplet technology
Taly, V., Pekin, D., Abed, A. I. E., & Laurent‐Puig, P. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.05.001 · Cited by 117
Identification of high-confidence somatic mutations in whole genome sequence of formalin-fixed breast cancer specimens
Yost, S. E., Smith, E. N., Schwab, R. B., Bao, L., Jung, H., Wang, X., Voest, E. E., Pierce, J. P., Messer, K. S., Parker, B. A., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks299 · Cited by 95
High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?
Ye, X., Zhu, Z.-Z., Zhong, L., Lu, Y., Sun, Y., Yin, X., Yang, Z., Zhu, G., & Ji, Q. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829f691f · Cited by 79
The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis
Lü, S., Ding, D., Yu, Y., Li, Z., & Niu, X. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s58870 · Cited by 41
Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients
Li, H., Hu, H., Wang, R., Pan, Y., Wang, L., Li, Y., Zhang, Y., Ye, T., Zhang, Y., Li, B., et al. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s60122 · Cited by 40
Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation
Ono, A., Kenmotsu, H., Watanabe, M., Serizawa, M., Mori, K. P., Imai, H., Taira, T., Naito, T., Murakami, H., Nakajima, T., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu251 · Cited by 38
The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis
Ding, D., Yu, Y., Li, Z., Niu, X., & Lu, S. (2014) · Dove Medical Press (Taylor and Francis Group) · Cited by 22
Driver mutations associated with smoking and other environmental factors: Prospective and integrative genomic analysis from the Japan Molecularepidemiology for Lung Cancer Study (JME).
Ito, N., Kawaguchi, T., Koh, Y., Isa, S., Shimizu, S., Takeo, S., Adachi, H., Tagawa, T., Kakegawa, S., Yamashita, M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.7516 · Cited by 2

Sorted by citations

Understanding and targeting resistance mechanisms in NSCLC
Rotow, J. K., & Bivona, T. G. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.84 · Cited by 997
Advances in studies of tyrosine kinase inhibitors and their acquired resistance
Jiao, Q., Bi, L., Ren, Y., Song, S., Wang, Q., & Wang, Y. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0801-5 · Cited by 414
Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
Remón, J., Steuer, C. E., Ramalingam, S. S., & Felip, E. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx704 · Cited by 332
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016
Tan, D. S. W., Yom, S. S., Tsao, M. S., Pass, H. I., Kelly, K., Peled, N., Yung, R. C., Wistuba, I. I., Yatabe, Y., Unger, M., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.008 · Cited by 201
Current and Emerging Applications of Droplet Digital PCR in Oncology
López, S. O., García‐Arranz, M., & García‐Olmo, D. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-017-0278-8 · Cited by 208

See all 216

Authors: Watanabe, M., Kawaguchi, T., Isa, S.-I., Ando, M., Tamiya, A., Kubo, A., Saka, H., Takeo, S., Adachi, H., Tagawa, T., Kakegawa, S., Yamashita, M., Kataoka, K., Ichinose, Y., Takeuchi, Y., Sakamoto, K., Matsumura, A., & Koh, Y.
Affiliations: Wakayama Medical University (JP)
Osaka City University (JP)
NHO Kinki Chuo Chest Medical Center (JP)
Nagoya University Hospital (JP)
Aichi Medical University (JP)
National Hospital Organization (JP)
National Kyushu Medical Center (JP)
Sapporo National Hospital (JP)
Nagasaki Medical Center (JP)
Shikoku Cancer Center (JP)
Iwakuni Medical Center (JP)
National Hospital Organization Kyushu Cancer Center (JP)
Toneyama National Hospital (JP)
National Hospital Organization Yokohama Medical Center (JP)
Corresponding author: Koh, Yasuhiro
ORCID: Watanabe, Masaru
Kawaguchi, Tomoya
Ando, Masahiko
Tamiya, Akihiro
Kubo, Akihito
Saka, Hideo
Sakamoto, Kazuhiro
Koh, Yasuhiro
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2015-08-01
Volume: 21
Issue: 15
Pages: 3552-3560
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-14-2151
OpenAlex: W2006126363
Cited by: 216
References: 42
Citations by year: 2026: 1 · 2025: 4 · 2024: 3 · 2023: 9 · 2022: 24 · 2021: 19 · 2020: 22 · 2019: 30 · 2018: 19 · 2017: 47 · 2016: 32 · 2015: 6
FWCI: 27.38
Type: journal article
Language: en
Open access: closed
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Funders: Japan Society for the Promotion of Science (25460896, 23501314)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords: T790M mutation, non-small cell lung cancer, EGFR activating mutations, droplet digital PCR, EGFR tyrosine kinase inhibitors, acquired drug resistance, tumor size, analytical sensitivity
MeSH terms: Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Gene Frequency, Humans, Male, Middle Aged, Mutation, Polymerase Chain Reaction, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Precision Medicine, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks